Residual disease detected by multidimensional flow cytometry shows prognostic significance in childhood acute myeloid leukemia with intermediate cytogenetics and negative FLT3-ITD: a report from the Tokyo Children's Cancer Study Group

International Journal of Hematology
Dai KeinoAkira Ohara

Abstract

Residual disease (RD) after induction chemotherapy may predict clinical outcome in acute myeloid leukemia (AML). In the present study, we investigated the prognostic significance of RD detected by multidimensional flow cytometry (MDF) among 34 children treated for AML in a clinical trial (JPLSG AML-05) in Japan. Bone marrow samples were analyzed at the points of the end of the first induction course (BMA-1) and second induction course (BMA-2) by MDF. RD was evaluated by detecting the immature cells showing abnormal antigen expression pattern; CD34(+), CD15(+), CD7(+). Thirteen (39.4 %) of 34 patients at BMA-1 and 8 (27.6 %) of 34 at BMA-2 had RD levels ≥0.1 %. There was no significant difference in 3y-EFS and 3y-OS between patients with RD levels ≥0.1 % and those with RD levels <0.1 % (53.8 versus 70.0 %, P = 0.30 and 50.0 versus 66.7 %, P = 0.27, respectively). However, IR cytogenetics and negative FLT3-ITD patients with RD levels ≥0.1 % exhibited significantly lower 3y-EFS and 3y-OS than those with RD levels <0.1 % (33.3 versus 83.3 %, P = 0.02 and 20.0 versus 76.9 %, P = 0.005, respectively). Our study suggests that RD shows prognostic relevance in pediatric patients with IR cytogenetics and negative FLT3-ITD AML.

References

Mar 20, 1993·Annals of the New York Academy of Sciences·G T StelzerM R Loken
Oct 9, 2003·British Journal of Haematology·Elaine Coustan-SmithDario Campana
Dec 16, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bruce D ChesonUNKNOWN International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards
Aug 1, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·UNKNOWN MRD-AML-BFM Study GroupDirk Reinhardt
Aug 17, 2006·Blood·Soheil MeshinchiJerald P Radich
Sep 20, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ursula CreutzigDirk Reinhardt
Jun 20, 2007·Leukemia Research·Michael R LokenDenise A Wells
Jul 22, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ichiro TsukimotoRyoji Hanada
Dec 15, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jonas AbrahamssonHenrik Hasle
Dec 24, 2010·JAMA : the Journal of the American Medical Association·Andrew J GentlesAsh A Alizadeh
Jan 12, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ching-Hon PuiRobert J Arceci
Mar 10, 2011·British Journal of Haematology·Gert J OssenkoppeleGerrit Jan Schuurhuis
Sep 12, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Hiroto InabaDario Campana

❮ Previous
Next ❯

Citations

Mar 13, 2021·Expert Review of Anticancer Therapy·W H SegerinkG J L Kaspers

❮ Previous
Next ❯

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.